What are the recommended dosing, administration route, indications, contraindications, and monitoring parameters for caspofungin in adult patients?

Caspofungin Dosing and Clinical Use

For adult patients, administer caspofungin as a 70-mg IV loading dose on Day 1, followed by 50 mg IV daily, infused slowly over approximately 1 hour—never as a bolus. 1

Indications

Caspofungin is FDA-approved for:

• Empirical therapy for presumed fungal infections in febrile neutropenic patients 1
• Candidemia and invasive candidiasis (intra-abdominal abscesses, peritonitis, pleural space infections) 2, 1
• Esophageal candidiasis 2, 1
• Invasive aspergillosis in patients refractory to or intolerant of other therapies (salvage therapy, not first-line) 1

Important limitation: Caspofungin has NOT been studied in Candida endocarditis, osteomyelitis, or meningitis 1

Route of Administration

• Intravenous infusion only over approximately 1 hour 1
• Never administer as IV bolus 1

Dosing Regimens by Indication

Candidemia and Invasive Candidiasis

• Loading dose: 70 mg IV on Day 1
• Maintenance: 50 mg IV daily
• Duration: Continue for at least 14 days after the last positive blood culture 2, 1
• If inadequate response and well-tolerated, increase to 70 mg daily 2, 1

Esophageal Candidiasis

• No loading dose for this indication 1
• Dose: 50 mg IV daily
• Duration: 7-14 days after symptom resolution 1

Invasive Aspergillosis (Salvage Therapy)

• Loading dose: 70 mg IV on Day 1
• Maintenance: 50 mg IV daily
• Duration: Based on underlying disease severity, immunosuppression recovery, and clinical response 1

Empirical Therapy in Febrile Neutropenia

• Loading dose: 70 mg IV on Day 1
• Maintenance: 50 mg IV daily
• Continue until neutropenia resolves; if fungal infection confirmed, treat minimum 14 days after last positive culture 2, 1
• Escalate to 70 mg daily if 50 mg well-tolerated but inadequate response 1

Special Populations

Hepatic Impairment

• Mild impairment (Child-Pugh 5-6): No adjustment needed 1
• Moderate impairment (Child-Pugh 7-9): 70-mg loading dose on Day 1, then reduce maintenance to 35 mg daily 1
• Severe impairment (Child-Pugh >9): No clinical data available; use with extreme caution 1

Renal Impairment

• No dose adjustment required regardless of renal function 1

Drug Interactions Requiring Dose Adjustment

When co-administered with hepatic enzyme inducers:

• Rifampin, efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine: Increase maintenance dose to 70 mg daily in adults 1

Pediatric Dosing (3 months to 17 years)

• Loading dose: 70 mg/m² IV on Day 1 (maximum 70 mg)
• Maintenance: 50 mg/m² IV daily (maximum 70 mg)
• Calculate using Mosteller Formula for body surface area 1

Contraindications

Hypersensitivity to caspofungin or any component of the formulation 1

Monitoring Parameters

Therapeutic Drug Monitoring

• Target trough concentration (Cmin): >1 mg/L for acceptable exposure 3
• Optimal efficacy threshold: >3.58 μg/mL based on recent data 4
• Consider TDM in:
  • Critically ill patients with altered volume of distribution 3
  • Patients with severe hypoalbuminemia 3, 5
  • Body weight >70 kg (may require higher doses of 70-150 mg) 5
  • Treatment failure 3
  • ICU patients (tend to have lower exposure) 5

Laboratory Monitoring

• Liver function tests: Monitor ALT, AST, alkaline phosphatase, and bilirubin regularly 1
• Electrolytes: Particularly potassium and magnesium 1
• Renal function: Monitor for changes, though dose adjustment not typically required 1

Clinical Monitoring

• Blood cultures: Repeat to document clearance; continue therapy 14 days after last positive culture 2, 1
• Imaging: For persistent candidemia, obtain CT or ultrasound of genitourinary tract, liver, and spleen to assess for metastatic complications 2
• Ophthalmologic exam: Dilated retinal examination for candidemia patients to rule out endophthalmitis 2
• Source control: Remove central venous catheters as early as safely possible in candidemia 3, 2

Common Pitfalls

1. Inadequate dosing in obese or hypoalbuminemic patients: Standard 50 mg may result in subtherapeutic levels; consider 70 mg maintenance dose 5, 4

2. Cyclosporine co-administration: Can cause transient ALT/AST elevations; monitor liver enzymes closely and reassess risk/benefit 1

3. Premature discontinuation: Especially in chronic disseminated candidiasis—continue until lesions resolve on imaging (usually several months) 2

4. Forgetting loading dose: Always use 70-mg loading dose except for esophageal candidiasis 1

5. Missing drug interactions: Failure to increase dose to 70 mg daily when using enzyme inducers results in treatment failure 1